Erratum to “Intratumoral Heterogeneity of MAGE-C1/CT7 and MAGE-C2/CT10 Expression in Mucosal Melanoma”

Curioni-Fontecedro, Alessandra; Pitocco, Rossella; Schoenewolf, Nicola L.; Holzmann, David; Soldini, Davide; Dummer, Reinhard; Calvieri, Stefano; Moch, Holger; Fitsche, André; Mihic‐Probst, Daniela

doi:10.1155/2019/5256364

Search citation statements

Order By: Relevance

Paper Sections

Select...

Cutaneous and Non-cutaneous Melanoma1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2020

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although most melanoma tumors develop in the skin (cutaneous melanoma), they can also arise in mucosal membranes, [10][11][12][13][14][15][16][17], in the eye (uveal melanoma) [18], and primary melanoma tumors have also been described in leptomeninges (Table 1) [19]. Among these different types of melanoma, cutaneous melanoma is by far the most prevalent.…”

Section: Cutaneous and Non-cutaneous Melanomamentioning

confidence: 99%

RAGE Signaling in Melanoma Tumors

Olaoba

Kadasah

Vetter

et al. 2020

IJMS

View full text Add to dashboard Cite

Despite recent progresses in its treatment, malignant cutaneous melanoma remains a cancer with very poor prognosis. Emerging evidences suggest that the receptor for advance glycation end products (RAGE) plays a key role in melanoma progression through its activation in both cancer and stromal cells. In tumors, RAGE activation is fueled by numerous ligands, S100B and HMGB1 being the most notable, but the role of many other ligands is not well understood and should not be underappreciated. Here, we provide a review of the current role of RAGE in melanoma and conclude that targeting RAGE in melanoma could be an approach to improve the outcomes of melanoma patients.

show abstract